Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

NCT05943210 · View on ClinicalTrials.gov ↗

Study Summary

This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.

Conditions Studied

Interventions

  • RADIATION Short Course Radiation Therapy (scRT)
  • PROCEDURE Total Mesenteric Excision (TME)

Study Locations (5)

New York

  • New York Presbyterian Brooklyn Methodist Hospital — Brooklyn
  • Weill Cornell Medical College — New York
  • New York Presbyterian Hospital - Queens — New York

Illinois

  • The University of Chicago — Chicago

New Jersey

  • Rutgers Cancer Institute of New Jersey — New Brunswick

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-05-22
Est. Completion 2028-05-31
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05943210

The ClinicalTrials.gov registry entry for NCT05943210 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 679 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions — of which Short Course Radiation Therapy (scRT) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05943210 reports 5 study locations spanning 3 distinct geographic areas — top geographies include New York, Illinois, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05943210 about?

NCT05943210 is a clinical study titled "The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer". This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.

What is the current status of trial NCT05943210?

This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2023-05-22. Estimated completion is 2028-05-31.

What conditions does trial NCT05943210 study?

This clinical trial studies the following conditions: Rectal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05943210?

The interventions under investigation include: Short Course Radiation Therapy (scRT) (RADIATION), Total Mesenteric Excision (TME) (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05943210?

This trial is sponsored by Weill Medical College of Cornell University, which has 679 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05943210 being conducted?

This trial has 5 study locations across Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial